new glp-1 receptor agonists approved for clinical use. GLP-1 agonists are available Comparing Ozempic, Wegovy and Other

The new label includes references to some of those postmarketing risks, including intestinal obstruction, [and] severe constipation including fecal impaction. Some patients who took Zepbound have filed lawsuits, accusing Eli Lilly of failing to properly warn them that Zepbound could increase their risk of severe gut problems, including bowel obstructions, pancreatitis, and gastroparesis

Early-access pricing reserved for waitlist members only, kept lower than open-market rates

Nausea is often worse during dose titration typically the first two to four weeks of therapy when gastric emptying and appetite change most rapidly

Cell Rep 2016

Wegovy is a weekly shot , while metformin is a daily pill

The prescription decision, the eligibility determination, and the medical judgment all belong to the independent licensed provider - not to the platform